Bleeding at Gastric Cancer
Conditions
Keywords
gastric cancer, bleeding, gastrointestinal hemorrhage
Brief summary
Gastrointestinal(GI) hemorrhage related with gastric cancer is prevalent in advanced cases mostly. As endoscopic hemostatic methods such as argon plasma ablation (APC) had developed, controlling GI hemorrhage in gastric cancer is much easier these days. but re-bleeding rate is still high, even after successful hemostasis with APC or electrical coagulation. Furthermore patients who were experienced re-bleeding are expected poorer survival outcomes than those who are not. So excellent bleeding control in gastric cancer is most important in GI hemorrhage of gastric cancer. Recently developed hemostatic powder \[Endo-Clot(TM)\] is easy to use and have proven its usefulness in GI hemorrhage in peptic ulcer diseases. So in this study, investigator will try to find out feasibility & safety of Endo-Clot(TM) in GI hemorrhage in gastric cancer.
Interventions
DRUGEndo-Clot(TM)
The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
Sponsors
Yonsei University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age over 19 and less 80 yeas old * Gastric cancer was diagnosed with biopsy and/or computed tomography * Endoscopic hemostasis is needed upto GI hemorrhage * Endoscopic examination is available in 24hours * ECOG performance status(PS) \<2
Exclusion criteria
* Double primary caner * Hypersensitivity of hemostatic power\[Endo-Clot(TM)\] * Variceal bleeding or benign gastric ulcer bleeding * Hemodynamically unstable with low systolic BP\<90mmHg and/or tachycardia PR\>120bpm * endoscopic hemostasis within 7 days before screening * Contraindication for endoscopic examination * Pregnant * Breast feeding * bleeding tendency with low platelet count \<50,000 /mm\^3 and/or INR\>2 * Bacterial infection with needs for antibiotics therapy * Unavailable to discontinue anti-coagulation agent for 3days * Vascular shunt * Cardiovascular and/or pulmonary diseases * Active hepatitis or severe liver diseases * Renal dysfunction * Bone marrow dysfunction * Neurologic deficit and/or psychotic feature * Unavailable informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rebleeding rate | within 30 days | Proportion of patients who are experience rebleeding events after hemostasis within 30 days expected to be lower than 10 %. Definition rebleeding events 1. Overt symptoms of GI bleeding(such as hematemesis, melena) and/or Hemoglobin down more than 2g/dl compared to Hemoglobin level which were checked just after procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Success of bleeding control rate | within 2 weeks and 4 weeks | Proportion of patients who are experience successful hemostasis is expected to be higher than 80 %applying Endo-Clot™, Rebleeding rate in 3days, rate of additional intervention other than initial endoscopic hemostasis, Mortalities |
| Rebleeding rate | in 3 days | Proportion of patients experience rebleeding events after hemostasis within 3 days expected to be lower than 5 %. Definition of Rebleeding rate in 3days 1. Overt symptoms of GI bleeding(such as hematemesis, melena) and/or Hemoglobin down more than 2g/dl compared to Hemoglobin level which were checked just after procedure. |
| Rate of additional intervention other than initial endoscopic hemostasis | within 2 weeks to 4 weeks | Definition of Successful hemostasis; controlled bleeding vessel in 5 minute after applying Endo-Clot™ |
| Mortalities | within 2 weeks to 4 weeks | — |
Countries
South Korea
Contacts
Primary ContactJun Chul Park, MD
Outcome results
None listed